⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13135828 | 0.78 | — | — | |
| SCHEMBL282872 | 0.76 | — | — | |
| SCHEMBL26767654 | 0.76 | MLYCD (0.32) | — | |
| SCHEMBL7942433 | 0.75 | KDM4E (0.36) | — | |
| SCHEMBL9768855 | 0.75 | SLC7A5 (0.33) | — | |
| SCHEMBL3370645 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL3026917 | 0.73 | — | — | |
| SCHEMBL23270909 | 0.71 | CA12 (0.32) | — | |
| SCHEMBL27270008 | 0.71 | — | — | |
| SCHEMBL27261495 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20210292349-A1 | PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1 | KANCERA AB (SE) | 2021-09-23 | — | — | US | disclosed |
| US-10654833-B2 | ASK1 isoindolin-1-one inhibitors and methods of use thereof | HEPATIKOS THERAPEUTICS, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20170217980-A1 | AMLEXANOX ANALOGS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-08-03 | — | — | US | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9585965-B2 | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-03-07 | — | — | US | disclosed |
| US-20160145296-A1 | BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2016-05-26 | — | — | US | disclosed |
| US-20160016951-A1 | NOVEL NAPHTHYRIDINES AND ISOQUINOLINES AND THEIR USE AS CDK8/19 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| EP-2425878-A1 | Protective coating compostition | Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO (NL) | 2012-03-07 | — | — | EP | disclosed |
| US-20110178092-A1 | HIV-1 Protease Inhibitors | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2011-07-21 | — | — | US | disclosed |
| US-20110178092-A1 | HIV-1 Protease Inhibitors | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2011-07-21 | — | — | US | disclosed |
| US-7709661-B2 | Synthetic methodology for the reductive alkylation at the C-3 position of indoles | WYETH LLC (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080161581-A1 | SYNTHETIC METHODOLOGY FOR THE REDUCTIVE ALKYLATION AT THE C-3 POSITION OF INDOLES | ZIARCO INC. | 2008-07-03 | — | — | US | disclosed |
| US-7282594-B2 | Synthetic methodology for the reductive alkylation at the C-3 position of indoles | WYETH (US) | 2007-10-16 | — | — | US | disclosed |
| US-5051518-A | Antiinflammatory agents and cardiovascular disorders | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-09-24 | — | — | US | disclosed |
| US-4059699-A | O,O-diethyl-O-carboxamidophosphate esters and use to combat insects and mites | GULF OIL CORPORATION (US) | 1977-11-22 | — | — | US | disclosed |
| US-3994997-A | MITICIDES, INSECTICIDES | GULF OIL CORPORATION (US) | 1976-11-30 | — | — | US | disclosed |